Clinical Trials
16 trialsNCT05730712 2026-05-15
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT02769962 2025-07-28
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT05655715 2024-10-16
CheckPRO
Herlev and Gentofte Hospital
Phase 2 Completed
NCT02933255 2024-05-31
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03225222 2023-09-07
MR-PROPER
Erasmus Medical Center
Completed
NCT05069584 2023-05-23
PERFECT
GCS Ramsay Santé pour l'Enseignement et la Recherche
Phase NA Completed
NCT04247217 2022-05-26
PRIMUS
Maastricht Radiation Oncology
Completed
NCT02229565 2020-11-13
GENCADE
Duke University
Completed
NCT00082147 2018-06-13
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT00898326 2017-06-02
SHIP36B
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Completed
NCT00373035 2017-01-19
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy
Wake Forest University Health Sciences
Completed
NCT00459407 2014-10-08
Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate
National Cancer Institute (NCI)
Phase 1 Completed
NCT00899665 2014-02-11
Proteases in Patients With Prostate Cancer That Has Spread to the Bone
Barbara Ann Karmanos Cancer Institute
Completed
NCT00416390 2013-09-20
Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia
National Cancer Institute (NCI)
Phase NA Completed
NCT00561314 2013-08-26
High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00562380 2013-07-18
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed